via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company")
(NASDAQ, TSX: NVCN) today announced that it will sponsor a
symposium entitled “Unmet Need in Treating Patients With Refractory
Angina” at the 2020 TCT Connect Online Conference, taking
place October 14-18, 2020.
The training session will be available via the TCT Connect
e-satellite for registered participants beginning Friday, October
16, at 7 AM EDT. The session will feature presentations by:
·
Prof. Tommaso Gori, MD, PhD, University Medical Center of Mainz,
Germany.
·
Timothy D. Henry, MD, Lindner Family Distinguished Chair in
Clinical Research and Medical Director of The Carl and Edyth
Lindner Center for Research at The Christ Hospital, Cincinnati,
OH.
·
Prof. Jonathan Michael Hill, Consultant Interventional Cardiologist
at Royal Brompton & Harefield NHS Foundation Trust, London,
U.K.
·
Gregg W. Stone, MD, Senior Faculty, Medicine, Cardiology,
Population Health Science and Policy, Icahn School of Medicine at
Mount Sinai, and Director, Academic Affairs, Mount Sinai Heart, New
York, N.Y.
·
Prof. Stefan Verheye, MD, PhD, Antwerp Cardiovascular Center, ZNA
Middelheim, Antwerp, Belgium.
About Reducer
The Reducer is CE-marked in the European Union for the treatment
of refractory angina, a painful and debilitating condition that
occurs when the coronary arteries deliver an inadequate supply of
blood to the heart muscle, despite treatment with standard
revascularization or cardiac drug therapies. It affects millions of
patients worldwide, who typically lead severely restricted lives as
a result of their disabling symptoms, and its incidence is growing.
The Reducer provides relief of angina symptoms by altering blood
flow within the myocardium of the heart and increasing the
perfusion of oxygenated blood to ischemic areas of the heart
muscle. Placement of the Reducer is performed using a minimally
invasive transvenous procedure that is similar to implanting a
coronary stent and is completed in approximately 20 minutes.
While the Reducer is not approved for commercial use in the
United States, the FDA granted Breakthrough Device designation to
the Reducer in October 2018. This designation is granted by
the FDA in order to expedite the development and review of a device
that demonstrates compelling potential to provide a more effective
treatment or diagnosis of life-threatening or irreversibly
debilitating diseases. In addition, there must be no FDA
approved treatments presently available, or the technology must
offer significant advantages over existing approved
alternatives.
Refractory angina, resulting in continued symptoms despite
maximal medical therapy and without revascularization options, is
estimated to affect 600,000 to 1.8 million Americans, with 50,000
to 100,000 new cases per year.1
1T. J. Povsic, S. Broderick, K. J. Anstrom et al., “Predictors
of long-term clinical endpoints in patients with refractory
angina,” Journal of the American Heart Association, vol. 4, no. 2,
article e001287, 2015.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops,
manufactures and markets products for the rapidly growing
cardiovascular marketplace. The Company is a leader in the
development of minimally invasive transcatheter mitral valve
replacement technologies, and minimally invasive devices for the
treatment of refractory angina. Its products include the Neovasc
Reducer™, for the treatment of refractory angina, which is not
currently commercially available in the United States (2 U.S.
patients have been treated under Compassionate Use) and has been
commercially available in Europe since 2015, and Tiara™, for the
transcatheter treatment of mitral valve disease, which is currently
under clinical investigation in the United States, Canada, Israel
and Europe. For more information,
visit: www.neovasc.com. Click here for a link to the
most recent corporate update.
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.866.4012
Sean.Leous@westwicke.com
Forward-Looking Statement Disclaimer
Certain statements in this news release contain
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws that may not be based on historical fact.
When used herein, the words "expect", "anticipate", "estimate",
"may", "will", "should", "intend," "believe", and similar
expressions, are intended to identify forward-looking
statements. Forward-looking statements may involve, but are
not limited to, the occurrence of and attendance at the E-Training
session, expectations as to the future growth of the Company, the
expansion of its product range and the growing cardiovascular
marketplace. Forward-looking statements are based on estimates and
assumptions made by the Company in light of its experience and its
perception of historical trends, current conditions and expected
future developments, as well as other factors that the Company
believes are appropriate in the circumstances. Many factors
could cause the Company's actual results, performance or
achievements to differ materially from those expressed or implied
by the forward-looking statements, including those described in the
"Risk Factors" section of the Company's Annual Report on Form 20-F
and in the Management's Discussion and Analysis for the three and
six months ended June 30, 2019 (copies of which may be obtained
at www.sedar.com or www.sec.gov). These
factors should be considered carefully, and readers should not
place undue reliance on the Company's forward-looking statements.
The Company has no intention and undertakes no obligation to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Sep 2023 to Sep 2024